Blocking the survival of the nastiest by HSP90 inhibition

It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers is responsible for therapeutic resistance – knowledge that is having a profound impact on current thinking and experimentation. There has been concern that molecularly targeted therapy is doomed to failure, with resistant clones emerging in response to the Darwinian selective pressure of any drug treatment. However, two studies have shown that the evolution of drug resistance can be restrained by co-administration of a pharmacologic inhibitor of the HSP90 molecular chaperone.

• Publication year

  2016

• Venue

  OncoTarget

• Publication date

  2016-01-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.18632/oncotarget.6971PMID 26820296PMCID 4826159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

  2014cited by this paper
• Cancer: evolution within a lifetime.

  2014influential reference
• HSP 90 empowers evolution of resistance to hormonal therapy in human breast cancer models

  2014cited by this paper
• HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models

  2014cited by this paper
• Combinatorial drug therapy for cancer in the post-genomic era

  2012cited by this paper
• Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

  2012influential reference
• Clonal evolution in cancer

  2012cited by this paper
• The clonal evolution of tumor cell populations.

  1976cited by this paper

• Hsp90 and cochaperones have two genetically distinct roles in regulating eEF2 function

  2024cites this paper
• Quantitative proteomic analysis reveals unique Hsp90 cycle-dependent client interactions

  2024cites this paper
• Linking hsp90's role as an evolutionary capacitator to the development of cancer.

  2021cites this paper
• Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer.

  2020cites this paper
• Chemical Perturbation of Oncogenic Protein Folding: from the Prediction of Locally Unstable Structures to the Design of Disruptors of Hsp90-Client Interactions.

  2020cites this paper
• Evolution of kinase polypharmacology across HSP90 drug discovery

  2020cites this paper
• The Hsp70-Hsp90 Chaperone Cascade in Protein Folding.

  2019cites this paper
• The Interplay between Structural Stability and Plasticity Determines Mutation Profiles and Chaperone Dependence in Protein Kinases.

  2018cites this paper
• System Biology to Access Target Relevance in the Research and Development of Molecular Inhibitors

  2018cites this paper
• Targeting protein quality control pathways in breast cancer

  2017cites this paper
• A comprehensive map of molecular drug targets

  2016cites this paper
• Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo

  2016cites this paper
• Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome.

  2016cites this paper